Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 220 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR ‘A significant step forwards’ – treating patients with advanced biliary tract... March 30, 2021 Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... July 7, 2021 Cómo mi diagnóstico de cáncer a los 17 años cambió mi... December 14, 2020 Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas June 27, 2023 Load more HOT NEWS How My Stage 4 Esophageal Cancer Diagnosis Led Me to a... Shaping Cancer Care in Asia: ESMO Brings Research and Patient Voices... A Safer, Better Treatment Option for Some Younger Women with Breast... Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment...
